UTI

UTI has compounded impressively: revenue has more than doubled from $335M (FY2021) to $836M (FY2025), and the Concorde acquisition plus organic growth drove FY2025 revenue +14.0%, operating income +41.7% to $83.5M, and diluted EPS +50.7% to $1.13. The 10-K confirms the quality of the move — both segments grew on higher full-time enrollment and new programs, with management explicitly crediting 'productivity improvements and proactive cost reductions.' Returns are now healthy (ROE 19.2%), the balance sheet is strengthening (long-term debt down 31.5% to $84.2M, equity +26.1% to $328M, retained earnings +163.6% to $102M), and operating cash flow of $97.3M comfortably funds the $42M of expansion capex (up 72.8%). This is a well-run, deleveraging growth story, not a turnaround.

The problem is price versus the underlying economics. At $41.35 the stock trades at 36.6x trailing EPS and 2.7x sales for a business whose net margin is only 7.5% and operating margin 10.0% — education services is structurally low-margin, so most of the bull case rests on continued margin expansion that is hard to extrapolate. After capex, free cash flow is roughly $55M, a ~2.4% yield on the $2.25B market cap. The headline EPS growth (+50%) flatters the picture because it laps the Concorde integration and one-time cost actions; the durable top-line rate is closer to the +14% reported, against which 36x is a full multiple. Cash also fell 21.3% as the company plowed money into campus/program expansion — a reasonable use, but it removes some cushion.